{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:43:26Z","timestamp":1783093406932,"version":"3.54.6"},"reference-count":192,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Renal cell carcinoma (RCC) is a prevalent and heterogeneous malignancy with clear cell RCC (ccRCC) as the most common subtype. Despite advances in surgical, targeted, and immunotherapeutic approaches, prognosis for advanced and metastatic RCC remains poor, and the effectiveness of current immunotherapies is limited by immune tolerance, tumor heterogeneity, and adverse effects. The identification of tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs) is crucial for the development of personalized and effective antigen-directed therapies, including vaccines, antibodies and adoptive cell therapies. This review summarizes epidemiological data, molecular features of RCC, and the role of the von Hippel Lindau \u2013 Hypoxia Inducible Factor (VHL-HIF) signaling pathway in pathogenesis, alongside recent progress in characterizing possible antigen targets for vaccination such as TOP2A, NCF4, FMNL1, DOK3, MUC1, CAIX, CD70, and 5T4. Preclinical models, including genetically engineered mouse models, zebrafish, and various patient-derived xenograft (PDX) systems, are discussed as tools for studying tumor biology and testing immunotherapeutic strategies. Clinical trial data on RCC vaccines, including autologous renal tumor cell vaccination, peptide-based, dendritic cell-based, and viral vector platforms, demonstrate immunogenicity but have not yet yielded clear survival benefits in phase III trials. Future directions emphasize integrating antigen discovery with immune profiling, refining preclinical modeling, and developing personalized vaccines to enhance therapeutic efficacy, particularly for immunologically favorable patient subtypes and for certain applications such as reducing metastasis after surgery. In particular, we discuss carrier-based vaccine approaches for overcoming tolerance and increasing the immunogenicity of vaccines.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1771006","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:37:40Z","timestamp":1774593460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Discovery of tumor antigens in renal cell carcinoma and prospects for clinical application"],"prefix":"10.3389","volume":"17","author":[{"given":"Evelina","family":"Kagirova","sequence":"first","affiliation":[{"name":"Institute of Urology and Clinical Oncology, Bashkir State Medical University","place":["Ufa, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadriia","family":"Enikeeva","sequence":"additional","affiliation":[{"name":"Institute of Urology and Clinical Oncology, Bashkir State Medical University","place":["Ufa, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radmir","family":"Mukhamadeev","sequence":"additional","affiliation":[{"name":"Institute of Urology and Clinical Oncology, Bashkir State Medical University","place":["Ufa, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilara","family":"Asadullina","sequence":"additional","affiliation":[{"name":"Institute of Urology and Clinical Oncology, Bashkir State Medical University","place":["Ufa, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Sharifyanova","sequence":"additional","affiliation":[{"name":"Institute of Urology and Clinical Oncology, Bashkir State Medical University","place":["Ufa, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Shmelkova","sequence":"additional","affiliation":[{"name":"Institute of Urology and Clinical Oncology, Bashkir State Medical University","place":["Ufa, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gainullina","sequence":"additional","affiliation":[{"name":"Institute of Urology and Clinical Oncology, Bashkir State Medical University","place":["Ufa, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Trifonova","sequence":"additional","affiliation":[{"name":"Division of Immunopathology, Department of Pathophysiology and Allergy Research, Medical University of Vienna","place":["Vienna, Austria"]},{"name":"Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University","place":["Moscow, Russia"]},{"name":"Laboratory of Immunology and Infectiology, Life Improvement by Future Technologies (LIFT) Center","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Gattinger","sequence":"additional","affiliation":[{"name":"Division of Immunopathology, Department of Pathophysiology and Allergy Research, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Docena","sequence":"additional","affiliation":[{"name":"Instituto de Estudios Inmunol\u00f3gicos y Fisiopatol\u00f3gicos-Instituto de Estudios Inmunol\u00f3gicos y Fisiopatol\u00f3gicos (IIFP), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET)","place":["La Plata, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Dubovets","sequence":"additional","affiliation":[{"name":"Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University","place":["Moscow, Russia"]},{"name":"Laboratory of Immunology and Infectiology, Life Improvement by Future Technologies (LIFT) Center","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Tulaeva","sequence":"additional","affiliation":[{"name":"Division of Immunopathology, Department of Pathophysiology and Allergy Research, Medical University of Vienna","place":["Vienna, Austria"]},{"name":"Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University","place":["Moscow, Russia"]},{"name":"Laboratory of Immunology and Infectiology, Life Improvement by Future Technologies (LIFT) Center","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Karaulov","sequence":"additional","affiliation":[{"name":"Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University","place":["Moscow, Russia"]},{"name":"Laboratory of Immunology and Infectiology, Life Improvement by Future Technologies (LIFT) Center","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Valenta","sequence":"additional","affiliation":[{"name":"Division of Immunopathology, Department of Pathophysiology and Allergy Research, Medical University of Vienna","place":["Vienna, Austria"]},{"name":"Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University","place":["Moscow, Russia"]},{"name":"Laboratory of Immunology and Infectiology, Life Improvement by Future Technologies (LIFT) Center","place":["Moscow, Russia"]},{"name":"Center for Molecular Allergology, Karl Landsteiner University for Healthcare Sciences","place":["Krems, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Pavlov","sequence":"additional","affiliation":[{"name":"Institute of Urology and Clinical Oncology, Bashkir State Medical University","place":["Ufa, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2016.08.006","article-title":"Metastasis in renal cell carcinoma: Biology and implications for therapy","volume":"3","author":"Gong","year":"2016","journal-title":"Asian J Urology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.1905","article-title":"Epidemiology and risk factors for kidney cancer","volume":"36","author":"Scelo","year":"2018","journal-title":"JCO"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112338-20220624-00558","article-title":"Global incidence and mortality of renal cell carcinoma in 2020","volume":"44","author":"Hu","year":"2023","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"B4","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014Part A: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16234034","article-title":"The current state of the diagnoses and treatments for clear cell renal cell carcinoma","volume":"16","author":"Quinn","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","article-title":"Renal cancer","volume":"387","author":"Capitanio","year":"2016","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21873\/invivo.13049","article-title":"An overview of epigenetics in clear cell renal cell carcinoma","volume":"37","author":"Grammatikaki","year":"2023","journal-title":"In Vivo"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2699","article-title":"Integrated molecular analysis of clear-cell renal cell carcinoma","volume":"45","author":"Sato","year":"2013","journal-title":"Nat Genet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01400","article-title":"Biomarkers of prognosis and efficacy of anti-angiogenic therapy in metastatic clear cell renal cancer","volume":"9","author":"D\u2019Aniello","year":"2019","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.15586\/jkcvhl.v12i2.387","article-title":"First-line ipilimumab with nivolumab versus immune checkpoint inhibitors with tyrosine kinase inhibitors in patients with intermediate- or poor-risk metastatic clear cell renal cell carcinoma","volume":"12","author":"Ostrowski","year":"2025","journal-title":"J Kidney Cancer VHL"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e251201","DOI":"10.1001\/jamanetworkopen.2025.1201","article-title":"Treatment and attrition trends for metastatic clear cell renal cell carcinoma in the US","volume":"8","author":"Ozay","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8020207","article-title":"Chimeric antigen receptor T-cells: the future is now","volume":"8","author":"Mchayleh","year":"2019","journal-title":"JCM"},{"key":"B15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3233\/KCA-230006","article-title":"Antigenic targets in clear cell renal cell carcinoma","volume":"7","author":"Schindler","year":"2023","journal-title":"KCA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0291","article-title":"FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines","volume":"71","author":"Kreiter","year":"2011","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature14320","article-title":"Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients","volume":"519","author":"Mitchell","year":"2015","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0112","article-title":"Human tumor antigens yesterday, today, and tomorrow","volume":"5","author":"Finn","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028829","article-title":"Is it possible to develop cancer vaccines to neoantigens, what are the major challenges, and how can these be overcome?: neoantigens: nothing new in spite of the name","volume":"10","author":"Finn","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra072739","article-title":"Cancer immunology","volume":"358","author":"Finn","year":"2008","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2022.03.011","article-title":"mRNA cancer vaccines: Advances, trends and challenges","volume":"12","author":"He","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1101\/gr.165985.113","article-title":"Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival","volume":"24","author":"Brown","year":"2014","journal-title":"Genome Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-567933","article-title":"Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia","volume":"124","author":"Rajasagi","year":"2014","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1001236","DOI":"10.1080\/2162402X.2014.1001236","article-title":"Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma","volume":"4","author":"Combe","year":"2015","journal-title":"OncoImmunology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/all.12661","article-title":"Poor association of allergen-specific antibody, T- and B-cell responses revealed with recombinant allergens and a CFSE dilution-based assay","volume":"70","author":"Eckl-Dorna","year":"2015","journal-title":"Allergy"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/antib13040085","article-title":"Preventative cancer vaccine-elicited human anti-MUC1 antibodies have multiple effector functions","volume":"13","author":"McKeague","year":"2024","journal-title":"Antibodies"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3934\/mbe.2023100","article-title":"Dissection of tumor antigens and immune landscape in clear cell renal cell carcinoma: Preconditions for development and precision medicine of mRNA vaccine","volume":"20","author":"Hu","year":"2022","journal-title":"MBE"},{"key":"B33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-021-01465-w","article-title":"Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma","volume":"20","author":"Xu","year":"2021","journal-title":"Mol Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0059-4","article-title":"Generation of autochthonous mouse models of clear cell renal cell carcinoma: mouse models of renal cell carcinoma","volume":"50","author":"Hou","year":"2018","journal-title":"Exp Mol Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2192","article-title":"Maximizing mouse cancer models","volume":"7","author":"Frese","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606857","article-title":"Genetically engineered mouse models in oncology research and cancer medicine","volume":"9","author":"Kersten","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/science.8493574","article-title":"Identification of the von hippel-lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/ng0594-85","article-title":"Mutations of the VHL tumour suppressor gene in renal carcinoma","volume":"7","author":"Gnarra","year":"1994","journal-title":"Nat Genet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3241","article-title":"Renal cyst development in mice with conditional inactivation of the von hippel-lindau tumor suppressor","volume":"66","author":"Rankin","year":"2006","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.197","article-title":"Conditional inactivation of the mouse von Hippel\u2013Lindau tumor suppressor gene results in wide-spread hyperplastic, inflammatory and fibrotic lesions in the kidney","volume":"34","author":"Pritchett","year":"2015","journal-title":"Oncogene"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e31034","DOI":"10.1371\/journal.pone.0031034","article-title":"Renal tubular HIF-2\u03b1 Expression requires VHL inactivation and causes fibrosis and cysts","volume":"7","author":"Schietke","year":"2012","journal-title":"PloS One"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010121249","article-title":"Hypoxia-inducible transcription factors stabilization in the thick ascending limb protects against ischemic acute kidney injury","volume":"22","author":"Schley","year":"2011","journal-title":"J Am Soc Nephrology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.024380","article-title":"Loss of vhl in the zebrafish pronephros recapitulates early stages of human clear cell renal cell carcinoma","volume":"9","author":"Noonan","year":"2016","journal-title":"Dis Models Mechanisms"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003643","article-title":"A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma","volume":"4","author":"Sivanand","year":"2012","journal-title":"Sci Transl Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12943-015-0384-3","article-title":"Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo","volume":"14","author":"Chang","year":"2015","journal-title":"Mol Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"8","DOI":"10.21037\/sci-2022-029","article-title":"An autologous humanized patient-derived xenograft (PDX) model for evaluation of nivolumab immunotherapy in renal cell cancer: a case report","volume":"9","author":"Kang","year":"2022","journal-title":"Stem Cell Investig"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2008.96","article-title":"pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation","volume":"27","author":"Frew","year":"2008","journal-title":"EMBO J"},{"key":"B49","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discovery"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1699-0463.1969.tb04520.x","article-title":"Heterotransplantation of A human Malignant tumour to \u201cNude\u201d Mice","volume":"77","author":"Rygaard","year":"1969","journal-title":"Acta Pathologica Microbiologica Scandinavica"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.628636","article-title":"The application progress of patient-derived tumor xenograft models after cholangiocarcinoma surgeries","volume":"11","author":"Wu","year":"2021","journal-title":"Front Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw041","article-title":"Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies","volume":"27","author":"Sanmamed","year":"2016","journal-title":"Ann Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Intl J Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/0471141755.ph1422s59","article-title":"Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research","volume":"59","author":"Lum","year":"2012","journal-title":"CP Pharmacol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000158043.94525.d6","article-title":"Independent validation of the 2002 american joint committee on cancer primary tumor classification for renal cell carcinoma using A large, single institution cohort","volume":"173","author":"Frank","year":"2005","journal-title":"J Urol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2921-T","article-title":"High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development","volume":"74","author":"Lin","year":"2014","journal-title":"Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e112371","DOI":"10.1371\/journal.pone.0112371","article-title":"Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts","volume":"9","author":"Miles","year":"2014","journal-title":"PloS One"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17765","article-title":"Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models","volume":"8","author":"Hong","year":"2017","journal-title":"Oncotarget"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2014.108","article-title":"Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing","volume":"9","author":"Pav\u00eda-Jim\u00e9nez","year":"2014","journal-title":"Nat Protoc"},{"key":"B60","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-017-0470-7","article-title":"Current status and perspectives of patient-derived xenograft models in cancer research","volume":"10","author":"Lai","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.19","article-title":"Patient-derived xenografts as in vivo models for research in urological Malignancies","volume":"14","author":"Inoue","year":"2017","journal-title":"Nat Rev Urol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2018.11.04","article-title":"Patient-derived xenograft models to optimize kidney cancer therapies","volume":"8","author":"Patel","year":"2019","journal-title":"Transl Androl Urol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1159\/000444533","article-title":"Patient-derived xenograft: an adjuvant technology for the treatment of metastatic disease","volume":"83","author":"Bousquet","year":"2016","journal-title":"Pathobiology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1242\/dmm.000976","article-title":"Mouse xenograft models vs GEM models for human cancer therapeutics","volume":"1","author":"Richmond","year":"2008","journal-title":"Dis Models Mech"},{"key":"B65","unstructured":"Renal cell carcinoma treatment & Management: approach considerations, surgical treatment, interleukin-2 and interferon\n          \n          \n          2024"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-010-0540-8","article-title":"Prognostic factors in renal cell carcinoma","volume":"28","author":"Volpe","year":"2010","journal-title":"World J Urol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9114","article-title":"Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model","volume":"7","author":"Suarez","year":"2016","journal-title":"Oncotarget"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3047","article-title":"Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment","volume":"20","author":"Garralda","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0115-0","article-title":"Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice","volume":"50","author":"Choi","year":"2018","journal-title":"Exp Mol Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.987682","article-title":"Editorial: in vitro and in vivo non-clinical models of kidney cancers","volume":"12","author":"Dormoy","year":"2022","journal-title":"Front Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13058-018-1037-4","article-title":"Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models","volume":"20","author":"Rosato","year":"2018","journal-title":"Breast Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315201","article-title":"Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy","volume":"67","author":"Zhao","year":"2018","journal-title":"Gut"},{"key":"B73","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-019-0518-z","article-title":"Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts","volume":"7","author":"Capasso","year":"2019","journal-title":"J immunotherapy cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.870396","article-title":"Advances in renal cell carcinoma drug resistance models","volume":"12","author":"Xiang","year":"2022","journal-title":"Front Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2012.117","article-title":"Cancer\/testis antigens and urological Malignancies","volume":"9","author":"Kulkarni","year":"2012","journal-title":"Nat Rev Urol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1177\/10668969211012085","article-title":"Immunohistochemical detection of cancer-testis antigen PRAME","volume":"29","author":"Lezcano","year":"2021","journal-title":"Int J Surg Pathol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0403572101","article-title":"Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans","volume":"101","author":"Davis","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.151955","article-title":"Dual targeting of ENPP3 and SIRP\u03b1 with a bispecific antibody enhances macrophage-mediated immunity in renal cell carcinoma","volume":"769","author":"Xu","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114209","article-title":"Identification of the extracellular membrane protein ENPP3 as a major cGAMP hydrolase and innate immune checkpoint","volume":"43","author":"Mardjuki","year":"2024","journal-title":"Cell Rep"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5898","article-title":"Functions of anti-MAGE T-cells induced in melanoma patients under different vaccination modalities","volume":"68","author":"Connerotte","year":"2008","journal-title":"Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.7150\/jca.32675","article-title":"Genetic variations in MAGE-A11 predict the risk and survival of renal cell cancer","volume":"10","author":"Su","year":"2019","journal-title":"J Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2010.05.013","article-title":"Immunohistochemical expression of tumor antigens MAGE-A3\/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma","volume":"206","author":"Demirovi\u0107","year":"2010","journal-title":"Pathol - Res Practice"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001944","article-title":"PRAME expression in cancer. A systematic immunohistochemical study of >5800 epithelial and nonepithelial tumors","volume":"46","author":"Kaczorowski","year":"2022","journal-title":"Am J Surg Pathology"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16967","article-title":"Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential","volume":"25","author":"Naik","year":"2021","journal-title":"J Cell Mol Medi"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s43141-022-00376-7","article-title":"Correlation of preferentially expressed antigen of melanoma (PRAME) gene expression with clinical characteristics in acute leukemia patients","volume":"20","author":"Kulkarni","year":"2022","journal-title":"J Genet Eng Biotechnol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1121973","article-title":"PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer","volume":"14","author":"Van Amerongen","year":"2023","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061801","article-title":"PRAME promotes cervical cancer proliferation and migration via wnt\/\u03b2-catenin pathway regulation","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13474","article-title":"Expression of cancer\u2013testis antigens in the immune microenvironment of non-small cell lung cancer","volume":"17","author":"Hikmet","year":"2023","journal-title":"Mol Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123612","article-title":"Cancer testis antigens and immunotherapy: expression of PRAME is associated with prognosis in soft tissue sarcoma","volume":"12","author":"Albertsmeier","year":"2020","journal-title":"Cancers"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-02840-3","article-title":"Expression of cancer\u2013testis antigens in esophageal cancer and their progress in immunotherapy","volume":"145","author":"Zhang","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.01.033","article-title":"Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3\/4, and NY-ESO-1 in squamous cell carcinoma of the penis","volume":"68","author":"Hudolin","year":"2006","journal-title":"Urology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0091","article-title":"Melanoma: a prototype of cancer-testis antigen-expressing Malignancies","volume":"9","author":"Faramarzi","year":"2017","journal-title":"Immunotherapy"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1700\/1430.15817","article-title":"Clinical significance of immunohistochemical expression of cancer\/testis tumor-associated antigens (MAGE-A1, MAGE-A3\/4, NY-ESO-1) in patients with non-small cell lung cancer","volume":"100","author":"Grah","year":"2014","journal-title":"Tumori"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.92","article-title":"Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area","volume":"112","author":"Sideras","year":"2015","journal-title":"Br J Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.canlet.2017.02.031","article-title":"Roles of cancer\/testis antigens (CTAs) in breast cancer","volume":"399","author":"Li","year":"2017","journal-title":"Cancer Letters"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2016.1197241","article-title":"Cancer\/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers","volume":"45","author":"Salmaninejad","year":"2016","journal-title":"Immunol Investigations"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115703","article-title":"Cancer cell metabolism in hypoxia: role of HIF-1 as key regulator and therapeutic target","volume":"22","author":"Infantino","year":"2021","journal-title":"IJMS"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2021.145796","article-title":"Up-down regulation of HIF-1\u03b1 in cancer progression","volume":"798","author":"Rashid","year":"2021","journal-title":"Gene"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27154893","article-title":"HIF in gastric cancer: regulation and therapeutic target","volume":"27","author":"Li","year":"2022","journal-title":"Molecules"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3017","article-title":"HIF-2\u03b1 mediates hypoxia-induced LIF expression in human colorectal cancer cells","volume":"6","author":"Wu","year":"2015","journal-title":"Oncotarget"},{"key":"B103","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12957-022-02815-8","article-title":"HIF-1\u03b1 and Caspase-3 expression in aggressive papillary thyroid carcinoma","volume":"20","author":"Zhang","year":"2022","journal-title":"World J Surg Onc"},{"key":"B104","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.intimp.2017.01.014","article-title":"Hypoxia-inducing factor (HIF)-1\u03b1-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma","volume":"44","author":"Minami","year":"2017","journal-title":"Int Immunopharmacology"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061392","article-title":"Carbonic anhydrase IX: A renewed target for cancer immunotherapy","volume":"14","author":"Campos","year":"2022","journal-title":"Cancers"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.21873\/cdp.10157","article-title":"CAIX immunostaining in non-neoplastic renal diseases","volume":"2","author":"Yousef","year":"2022","journal-title":"CDP"},{"key":"B107","doi-asserted-by":"publisher","first-page":"535:111382","DOI":"10.1016\/j.mce.2021.111382","article-title":"Carbonic-anhydrase IX expression is increased in thyroid cancer tissue and represents a potential therapeutic target to eradicate thyroid tumor-initiating cells","volume":"15","author":"Schmidt","year":"2021","journal-title":"Mol Cell Endocrinology"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701006","article-title":"B7-H3\/CD276: an emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0116","article-title":"Preclinical development of MGC018, a duocarmycin-based antibody\u2013drug conjugate targeting B7-H3 for solid cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B110","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/ni967","article-title":"The B7 family member B7-H3 preferentially down-regulates T helper type 1\u2013mediated immune responses","volume":"4","author":"Suh","year":"2003","journal-title":"Nat Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.41105","article-title":"B7-H3, a checkpoint molecule, as a target for cancer immunotherapy","volume":"16","author":"Yang","year":"2020","journal-title":"Int J Biol Sci"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1917-3","article-title":"5T4 oncofoetal antigen: an attractive target for immune intervention in cancer","volume":"66","author":"Stern","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-7-2","article-title":"Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma","volume":"7","author":"Kaufman","year":"2009","journal-title":"J Transl Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"MUC1: a multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"Nath","year":"2014","journal-title":"Trends Mol Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910801)68:3%3C574::AID-CNCR2820680322%3E3.0.CO;2-B","article-title":"The value of the tumor marker CA 15\u20133 in diagnosing and monitoring breast cancer","volume":"68","author":"Safi","year":"1991","journal-title":"A Comp study carcinoembryonic antigen. Cancer"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0896(98)00092-3","article-title":"Effects of glycosylation on fragments of tumour associated human epithelial mucin MUC1","volume":"6","author":"Braun","year":"1998","journal-title":"Bioorganic Medicinal Chem"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines4030025","article-title":"Immunological evaluation of recent MUC1 glycopeptide cancer vaccines","volume":"4","author":"Hossain","year":"2016","journal-title":"Vaccines"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.12.4309","article-title":"Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies","volume":"93","author":"Brossart","year":"1999","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0935-9","article-title":"A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings","volume":"60","author":"Oudard","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B120","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101611","article-title":"Screening a broad range of solid and haematological tumour types for CD70 expression using a uniform IHC methodology as potential patient stratification method","volume":"11","author":"Flieswasser","year":"2019","journal-title":"Cancers"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.12.1793","article-title":"A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription","volume":"190","author":"Van Den Eynde","year":"1999","journal-title":"J Exp Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-2115","article-title":"Abstract 2115: SIM0680, a potent antibody-drug conjugate for the treatment of solid tumors expressing ENPP3","volume":"85","author":"Emran","year":"2025","journal-title":"Cancer Res"},{"key":"B124","doi-asserted-by":"publisher","first-page":"e003101","DOI":"10.1136\/jitc-2021-003101","article-title":"Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model","volume":"9","author":"He","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15044","article-title":"Co-immunization with L-Myc enhances CD8+ or CD103+ DCs mediated tumor-specific multi-functional CD8+ T cell responses","volume":"112","author":"Chai","year":"2021","journal-title":"Cancer Science"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197146","article-title":"Carbonic anhydrase IX in renal cell carcinoma, implications for disease management","volume":"21","author":"Courcier","year":"2020","journal-title":"IJMS"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1007\/BF02602776","article-title":"A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma","volume":"44","author":"Gaugler","year":"1996","journal-title":"Immunogenetics"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2011.10.014","article-title":"CD70 expression patterns in renal cell carcinoma","volume":"43","author":"Jilaveanu","year":"2012","journal-title":"Hum Pathology"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110888","article-title":"A review on development of MUC1-based cancer vaccine","volume":"132","author":"Gao","year":"2020","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1097\/00125480-199901000-00002","article-title":"A new melanocytic differentiation marker","volume":"6","author":"Busam","year":"1999","journal-title":"Adv Anatomic Pathol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15590-6","article-title":"Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial","volume":"363","author":"Jocham","year":"2004","journal-title":"Lancet"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.05.022","article-title":"Updated European association of urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma","volume":"76","author":"Albiges","year":"2019","journal-title":"Eur Urology"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2883","article-title":"Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival","volume":"18","author":"Walter","year":"2012","journal-title":"Nat Med"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30408-9","article-title":"IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"17","author":"Rini","year":"2016","journal-title":"Lancet Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3905","article-title":"Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients","volume":"66","author":"Wierecky","year":"2006","journal-title":"Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2253","article-title":"A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma","volume":"12","author":"Uemura","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.90","article-title":"Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma","volume":"108","author":"Yoshimura","year":"2013","journal-title":"Br J Cancer"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0580","article-title":"A randomized phase II\/III study of naptumomab estafenatox + IFN\u03b1 versus IFN\u03b1 in renal cell carcinoma: final analysis with baseline biomarker subgroup and trend analysis","volume":"22","author":"Hawkins","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B139","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00262-016-1915-5","article-title":"Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma","volume":"66","author":"Obara","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2007.tb03940.x","article-title":"WT1 (Wilms\u2019 Tumor 1) peptide immunotherapy for renal cell carcinoma","volume":"51","author":"Iiyama","year":"2007","journal-title":"Microbiol Immunol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12694","article-title":"Vaccination of urological cancer patients with WT1 peptide-pulsed dendritic cells in combination with molecular targeted therapy or conventional chemotherapy induces immunological and clinical responses","volume":"22","author":"Ogasawara","year":"2018","journal-title":"Ther Apher Dial"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(94)80017-0","article-title":"Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides","volume":"1","author":"Alexander","year":"1994","journal-title":"Immunity"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181d75820","article-title":"Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity","volume":"33","author":"Forsberg","year":"2010","journal-title":"J Immunother"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.140","article-title":"The dawn of vaccines for cancer prevention","volume":"18","author":"Finn","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.05.015","article-title":"Cancer vaccines","volume":"40","author":"Schiller","year":"2022","journal-title":"Cancer Cell"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2009.03443.x","article-title":"Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity","volume":"40","author":"Focke","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-030409-101218","article-title":"From allergen genes to allergy vaccines","volume":"28","author":"Valenta","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.imlet.2017.04.015","article-title":"Recombinant allergy vaccines based on allergen-derived B cell epitopes","volume":"189","author":"Valenta","year":"2017","journal-title":"Immunol Letters"},{"key":"B150","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jaci.2017.09.052","article-title":"Safety and efficacy of immunotherapy with the recombinant B-cell epitope\u2013based grass pollen vaccine BM32","volume":"142","author":"Niederberger","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11485","article-title":"Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2\/neu","volume":"107","author":"Jasinska","year":"2003","journal-title":"Intl J Cancer"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/nri1150","article-title":"Cancer vaccines: between the idea and the reality","volume":"3","author":"Finn","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1600-065X.1995.tb00077.x","article-title":"MUC-1 epithelial tumor mucin-based immunity and cancer vaccines","volume":"145","author":"Finn","year":"1995","journal-title":"Immunol Rev"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690288","article-title":"Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21","volume":"79","author":"Adluri","year":"1999","journal-title":"Br J Cancer"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1452814","article-title":"Fusion protein-based COVID-19 vaccines exemplified by a chimeric vaccine based on a single fusion protein (W-PreS-O)","volume":"16","author":"Gattinger","year":"2025","journal-title":"Front Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830240222","article-title":"Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine","volume":"24","author":"Hellman","year":"1994","journal-title":"Eur J Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1096\/fj.01-0879fje","article-title":"Generation of therapeutic antibody responses against IgE through vaccination","volume":"16","author":"Vernersson","year":"2002","journal-title":"FASEB J"},{"key":"B158","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1586\/14760584.7.2.193","article-title":"Therapeutic vaccines against IgE-mediated allergies","volume":"7","author":"Hellman","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1135","article-title":"Human antibodies from transgenic animals","volume":"23","author":"Lonberg","year":"2005","journal-title":"Nat Biotechnol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1337","article-title":"From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice","volume":"25","author":"Jakobovits","year":"2007","journal-title":"Nat Biotechnol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2174\/15701638113109990038","article-title":"Transgenic mouse strains as platforms for the successful discovery and development of human therapeutic monoclonal antibodies","volume":"11","author":"Green","year":"2014","journal-title":"CDDT"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fc\u03b3 receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1038\/nri2744","article-title":"Monoclonal antibodies: versatile platforms for cancer immunotherapy","volume":"10","author":"Weiner","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell\u2013mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"B167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","article-title":"Decisions about dendritic cells: past, present, and future","volume":"30","author":"Steinman","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.866763","article-title":"Generation of tumor-specific cytotoxic T cells from blood via in vitro expansion using autologous dendritic cells pulsed with neoantigen-coupled microbeads","volume":"12","author":"Kiessling","year":"2022","journal-title":"Front Oncol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"B171","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"IJMS"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-06033-6","article-title":"mRNA vaccines in the context of cancer treatment: from concept to application","volume":"23","author":"Fu","year":"2025","journal-title":"J Transl Med"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00149","article-title":"Understanding the biology of antigen cross-presentation for the design of vaccines against cancer","volume":"5","author":"Fehres","year":"2014","journal-title":"Front Immunol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1084\/jem.143.5.1283","article-title":"Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay","volume":"143","author":"Bevan","year":"1976","journal-title":"J Exp Med"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02135-4","article-title":"Increased cross-presentation by dendritic cells and enhanced anti-tumour therapy using the Arp2\/3 inhibitor CK666","volume":"128","author":"Oliveira","year":"2023","journal-title":"Br J Cancer"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N Engl J Med"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"B181","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/jamacardio.2021.3471","article-title":"Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children","volume":"6","author":"Dionne","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/ehjqcco\/qcab090","article-title":"Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines","volume":"8","author":"Foltran","year":"2022","journal-title":"Eur Heart J - Qual Care Clin Outcomes"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158035","article-title":"Combining cancer vaccines with immunotherapy: establishing a new immunological approach","volume":"22","author":"Kim","year":"2021","journal-title":"IJMS"},{"key":"B186","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/14760584.2018.1506332","article-title":"Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy","volume":"17","author":"Collins","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00467","article-title":"Therapeutic cancer vaccine and combinations with antiangiogenic therapies and immune checkpoint blockade","volume":"10","author":"Mougel","year":"2019","journal-title":"Front Immunol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"B190","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"JCO"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2922","article-title":"Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2\/3 study of naptumomab estafenatox plus IFN-\u03b1 versus IFN-\u03b1","volume":"6","author":"Elkord","year":"2015","journal-title":"Oncotarget"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1771006\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:37:45Z","timestamp":1774593465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1771006\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":192,"alternative-id":["10.3389\/fimmu.2026.1771006"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1771006","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"article-number":"1771006"}}